Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNK | O75909 | 20/20 | 0.61 |
| ▸ | CDK12 | Q9NYV4 | 20/20 | 0.61 |
| ▸ | CDK13 | Q14004 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23292344 | 1.00 | CCNK (0.61) | CCNKCDK12CDK13 | |
| SCHEMBL22895516 | 1.00 | CCNK (0.61) | CCNKCDK12CDK13 | |
| SCHEMBL31548536 | 1.00 | CCNK (0.61) | CCNKCDK12CDK13 | |
| SCHEMBL23295769 | 0.94 | CCNK (0.57) | CCNKCDK12CDK13 | |
| SCHEMBL22895937 | 0.94 | CCNK (0.57) | CCNKCDK12CDK13 | |
| SCHEMBL23292276 | 0.94 | CCNK (0.57) | CCNKCDK12CDK13 | |
| SCHEMBL28559075 | 0.93 | CDK12 (0.54) | CCNKCDK12CDK13 | |
| SCHEMBL28559072 | 0.93 | CDK12 (0.54) | CCNKCDK12CDK13 | |
| SCHEMBL23292315 | 0.93 | CDK12 (0.54) | CCNKCDK12CDK13 | |
| SCHEMBL23292283 | 0.90 | CDK12 (0.55) | CCNKCDK12CDK13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11358958-B2 | — | — | 2022-06-14 | — | — | US | disclosed |
| US-20210130340-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASES | KINNATE BIOPHARMA INC. | 2021-05-06 | — | — | US | disclosed |
| CN-112638373-A | Cyclin-dependent kinase inhibitors | 金耐特生物制药公司 | 2021-04-09 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11358958-B2 | — | CDK2, CDK1, CDK6 | CCNK 7/4885CDK12 19/4885CDK13 37/4885 |
| US-20210130340-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASES | CDK2, CCNK, CDK1 | CCNK 2/4885CDK12 22/4885CDK13 39/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.